Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeuShen Therapeutics

Request full access

AAV-based gene therapy and small molecule discovery.

Jing'an District, ChinaFounded 2021Biotech & Life Sciences

About NeuShen Therapeutics

NeuShen Therapeutics is a clinical-stage biotechnology company founded in 2021 that specializes in developing treatments for psychiatric and neurological disorders. The company has research and development centers in Shanghai, China, and Boston, Massachusetts. NeuShen was founded by Dr. Joan Huaqiong Shen, a physician certified by the American Board of Psychiatry and Neurology with extensive experience in global pharmaceutical R&D at companies like Eli Lilly, Wyeth, Pfizer, Janssen, and I-Mab Biopharma.

The company focuses on central nervous system (CNS) disorders, an area with significant unmet medical needs. NeuShen utilizes a dual-modality approach, combining AAV-based gene therapy with small molecule discovery to create a pipeline of drug candidates. Their business model involves B2B partnerships and licensing agreements with healthcare providers, research institutions, and pharmaceutical companies. The company's pipeline includes treatments for conditions such as depression, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease. One of its lead assets, NS-136, is a selective M4 muscarinic acetylcholine receptor positive allosteric modulator (M4 PAM) being developed for schizophrenia and agitation in Alzheimer's disease. This compound has advanced to Phase 2 clinical trials. Another candidate, NS-041, is a KCNQ2/3 potassium channel activator for focal onset seizures and major depressive disorder.

NeuShen has secured significant funding to advance its pipeline. In September 2022, the company closed a Pre-A financing round of approximately $20 million, led by Lapam Capital. This was followed by a Series A+ financing round in January 2026, led by Lilly Asia Ventures with participation from Pivotal bioVenture Partners and existing investors. These funds are being used to progress multiple programs through preclinical and clinical development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
80.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Core AI, Biotech and Pharma, Generative AI, Hard Tech, DT and LS, science-based
Technology
Artificial Intelligence
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2026 $80M $320M Matrix Partners China · Legend Capital · LAV · Shanghai Guotou Pioneer ↗
SERIES A✓Equity / VC Jan 2026 $20M $80M BioVenture · Longpan Investment · SHC Shanghai Biomedical Fund · Lilly Asia Ventures ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

NeuShen Therapeutics website traffic

Latest recorded traffic for NeuShen Therapeutics is 2K monthly website visits, up 66.7% over the last three months. NeuShen Therapeutics's team grew 20% over the past year.

Latest monthly visits2K 3-month web change+66.7% 1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NeuShen Therapeutics in the Jing'an District ecosystem

Live from Dealroom

The NeuShen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Lapam Capital
  • TTM Capital

Series A8 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States66.7%
🇨🇳 China33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeuShen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuShen Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.